T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies

Immunology

Volumn 131, Issue 3, 2010, Pages 371-376

  Lindqvist, Camilla A ^a   Christiansson, Lisa H ^a   Simonsson, Bengt ^b   Enblad, Gunilla ^b   Olsson Strömberg, Ulla ^b   Loskog, Angelica S I ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

B cell malignancy; CD25; Immune escape mechanism; Interleukin 2 receptor ; T regulatory cell

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; B CELL LEUKEMIA; CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

CELL PROLIFERATION; CELL SEPARATION; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOMA, B-CELL; RECOMBINANT PROTEINS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 78649439306     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2010.03308.x     Document Type: Article

References (15)

1. Létourneau S, Krieg C, Pantaleo G, Boyman O. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol 2009; 123:758-62.
2. Kuhn DJ, Dou QP. The role of interleukin-2 receptor alpha in cancer. Front Biosci 2005; 10:1462-74.
3. Perez-Encinas M, Villamayor M, Campos A, Gonzalez S, Bello JL. Tumor burden and serum level of soluble CD25, CD8, CD23, CD54 and CD44 in non-Hodgkin's lymphoma. Haematologica 1998; 83:752-4.
4. Fabre-Guillevin E, Tabrizi R, Coulon V, Monnereau A, Edhbali H, Soubeyran I, Soubeyran P. Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leuk Lymphoma 2006; 47:603-11.
5. Goto H, Tsurumi H, Takemura M et al. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol 2005; 131:73-9.
6. Caruso C, Candore G, Cigna D, Colucci AT, Modica MA. Biological significance of soluble IL-2 receptor. Mediators Inflamm 1993; 2:3-21.
7. Kay NE, Burton J, Wagner D, Nelson DL. The malignant B cells from B-chronic lymphocytic leukemia patients release TAC-soluble interleukin-2 receptors. Blood 1988; 72:447-50.
8. + regulatory T cells does not inhibit the action of IL-2. Scand J Immunol 2009; 70:40-3.
9. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nature Rev Immunol 2008; 8:523-32.
10. + T cell cytotoxicity and cancer. Semin Cancer Biol 2006; 16:124-36.
11. high regulatory T cells. Curr Protoc Immunol. 2006; Chapter 7:unit7:4B.
12. + regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods 2007; 319:41-52.
13. + regulatory T cells. Front Biosci 2008; 13:1440-6.
14. + T cells. Nature immunol 2007; 8:1353-62.
15. Kryczek I, Liu R, Wang G et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009; 69:3995-4000.